Modality
mRNA
MOA
MALT1i
Target
CFTR
Pathway
Tau
Urothelial Ca
Development Pipeline
Preclinical
~Jan 2021
→ ~Apr 2022
Phase 1
~Jul 2022
→ ~Oct 2023
Phase 2
~Jan 2024
→ ~Apr 2025
Phase 3
Jul 2025
→ Dec 2026
Phase 3Current
NCT04206220
2,703 pts·Urothelial Ca
2025-07→2026-12·Completed
NCT07328033
208 pts·Urothelial Ca
2025-11→2026-03·Active
2,911 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-03-093w agoPh3 Readout· Urothelial Ca
2026-12-179mo awayPh3 Readout· Urothelial Ca
Trial Timeline
Q3Q42026Q2Q3Q4
P3
Complet…
P3
Active
Catalysts
Ph3 Readout
2026-03-09 · 3w ago
Urothelial Ca
Ph3 Readout
2026-12-17 · 9mo away
Urothelial Ca
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04206220 | Phase 3 | Urothelial Ca | Completed | 2703 | LiverFat |
| NCT07328033 | Phase 3 | Urothelial Ca | Active | 208 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 |